NEW YORK (GenomeWeb News) — Shares in Affymetrix were up 17.74 percent, or $4.09, at $26.72 this afternoon after the company yesterday released its third-quarter earnings.
 
Today, investment bank UBS upgraded its rating of Affy shares to ‘Neutral’ from ‘Reduce.’
 
As GenomeWeb News reported yesterday, Affy said that third-quarter revenue increased around 1 percent as last year's profit swung to a loss.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.